Benjamin R S
Recent Results Cancer Res. 1978;63:230-40. doi: 10.1007/978-3-642-81219-4_21.
Adriamycin is now firmly established as a drug with a very broad spectrum of antitumor activity. It has had a major impact on the therapy of sarcomas. The dose response effect in this tumor is steep and combinations which compromise the dose of adriamycin too greatly are showing inferior results. In lung and breast cancer combinations with adriamycin have been extensively tried. The FAC Regimen in breast cancer has given excellent results at the M.D. Anderson Hospital. The inclusion of adriamycin in combinations has had an impact in the poor prognosis histologies of non-Hodgkin's lymphomas. The CHOP regimen is one of the best developed to date for diffuse histiocytic lymphomas. In the leukemias adriamycin is probably equivalent to daunorubicin which has been more extensively used in this country. A new analog called Rubidazone has shown good activity in AML with a smooth induction and its incorporation into combination with Ara-C, vincristine and prednisone in a regimen called ROAP is being investigated. Adriamycin in complex with DNA has been clinically evaluated, but at this time, no advantage for this approach can be demonstrated.
阿霉素现已被确认为一种具有非常广泛抗肿瘤活性的药物。它对肉瘤的治疗产生了重大影响。这种肿瘤的剂量反应效应很明显，极大地降低阿霉素剂量的联合用药显示出较差的效果。在肺癌和乳腺癌中，与阿霉素联合用药已得到广泛尝试。乳腺癌的FAC方案在MD安德森医院取得了优异的效果。在非霍奇金淋巴瘤预后较差的组织学类型中，联合使用阿霉素也产生了影响。CHOP方案是迄今为止针对弥漫性组织细胞淋巴瘤研发得最好的方案之一。在白血病中，阿霉素可能等同于柔红霉素，而柔红霉素在该国的使用更为广泛。一种名为鲁比达唑的新类似物在急性髓性白血病中显示出良好的活性，诱导过程平稳，目前正在研究将其与阿糖胞苷、长春新碱和泼尼松联合用于一种名为ROAP的方案。阿霉素与DNA复合物已进行临床评估，但目前尚无法证明这种方法具有优势。
